Pharmacy loans in Canada: what banks require and why applications get declined

Canadian banks typically finance 60 to 75 percent of a pharmacy’s purchase price, and the test most lenders apply is debt service coverage: the pharmacy’s cash available for debt service, measured against the annual loan payments, with about 1.25x the figure many look for. As a worked example, a $1.2 million loan at 6.5 percent over 10 years costs about $163,509 a year, so the pharmacy needs roughly $204,000 of cash available for debt service to reach 1.25x. The rest of the price comes from the buyer’s equity and, in some deals, a vendor take back. This guide covers what the banks check, the thresholds they use, and the reasons applications are declined.

Understanding how banks finance pharmacy acquisitions matters just as much to sellers as it does to buyers.

Sellers need buyers who can actually close. A buyer with inadequate financing wastes months of your time, disrupts your business through due diligence, and ultimately walks away when their bank rejects the loan. Meanwhile, you have lost momentum, leaked confidentiality, and potentially damaged other buyer relationships through your exclusivity period.

Buyers need realistic expectations about what they can afford and what banks require. Overestimating your financing capacity leads to accepted offers you cannot fund. Underestimating it means you miss opportunities or negotiate weak positions.

Canadian banks have specific criteria for pharmacy acquisition loans. They evaluate the business differently than other small businesses because they understand pharmacy economics, regulatory requirements, and typical cash flow patterns. Major banks like RBC, Scotiabank, TD, BMO, and CIBC have dedicated healthcare financing teams. Credit unions like Meridian, Coast Capital, and Servus also actively finance pharmacy purchases, often with more flexibility for local borrowers.

This guide explains exactly what Canadian banks evaluate when financing pharmacy acquisitions, the metrics that matter most, typical loan structures, and how both buyers and sellers can position themselves for successful financing.

The ranges and thresholds in this guide reflect what we see on recent Canadian pharmacy files. Every lender sets its own terms, so treat them as typical, not fixed.

Quick Summary: What You Will Learn

• The key financial metrics banks analyze for pharmacy loans
• How Debt Service Coverage Ratio (DSCR) determines loan amounts
• Typical down payment requirements and loan-to-value ratios
• What banks look for in pharmacy financial statements and operations
• How lease terms and location affect financing approval
• Differences between major banks and credit unions for pharmacy loans
• Why normalized EBITDA matters to lenders

What Canadian Banks Focus On When Financing Pharmacy Purchases

Banks approach pharmacy financing with two primary questions: Can this business generate enough cash flow to service the debt? Does the borrower have the capacity and commitment to manage the pharmacy successfully?

Unlike residential mortgages where property value drives lending decisions, pharmacy acquisition loans are primarily cash flow based. Banks care less about hard assets (inventory and equipment depreciate quickly) and more about sustainable earnings that can reliably cover loan payments with a comfortable margin.

Business Viability Assessment

Banks want pharmacies with proven track records of profitability and stable cash flow. They examine:

Historical financial performance: Three years of complete financial statements (profit and loss, balance sheet) and corporate tax returns. Banks look for consistent or growing revenue, stable margins, and positive EBITDA trends.

Prescription volume stability: Monthly prescription counts for 24 to 36 months. Banks want to see stable or increasing script volumes. Declining prescription counts raise immediate red flags about market share loss or demographic changes.

Revenue source diversification: Analysis of payer mix (provincial drug plans, private insurance, cash pay customers). Heavy reliance on a single payer or a few large institutional clients (like one nursing home contract representing 40% of revenue) creates concentration risk that concerns lenders.

Profitability sustainability: Banks assess whether current profitability is sustainable or inflated by temporary factors. For example, if a pharmacy’s EBITDA is heavily dependent on manufacturer rebates in provinces where they remain legal, banks will scrutinize whether those rebate agreements will continue.

Borrower Experience and Equity Contribution

The buyer’s qualifications matter enormously.

Professional credentials: Banks prefer buyers who are licensed pharmacists with direct industry experience. First-time pharmacy buyers with pharmacist credentials get better terms than business investors without pharmacy backgrounds.

Management experience: Prior experience managing a pharmacy (even as an associate pharmacist or relief manager) demonstrates operational capability. Banks view buyers who have never managed a pharmacy as higher risk.

Personal financial strength: The borrower’s personal net worth, credit score, and existing debt obligations all factor into approval decisions. A buyer with a strong personal balance sheet (home equity, investments, minimal consumer debt) receives more favourable terms.

Equity contribution: The amount of cash the buyer invests from personal funds signals commitment and affects loan terms. In the current market we see everything from 100% financing to lenders asking for up to 20% down on a good pharmacy with a good lease. Some lenders now advertise up to 100% financing (zero down payment) for qualified pharmacist buyers; Scotiabank’s pharmacist banking program is one example. Eligibility is set by each lender and is subject to credit approval. These programs tend to go to buyers with strong personal credit and pharmacy management experience, buying established pharmacies with comfortable debt coverage. Higher equity contributions still often result in better interest rates, more favourable terms, and easier approval. For marginal deals, first-time buyers or a short lease, the down payment goes up.

Purpose of Financing and Loan Structure

Canadian banks offer pharmacy financing for various purposes, each with different risk profiles:

• Acquisition financing: Purchasing an existing pharmacy (most common). These loans are evaluated based on the target pharmacy’s historical cash flow.
• Start-up or new pharmacy financing: Opening a new pharmacy from scratch. These loans are riskier and require stronger borrower credentials, detailed business plans, and often a 30% to 40% equity contribution.
• Expansion capital: Adding services, renovating facilities, or acquiring additional locations. Banks view expansion favourably if the existing pharmacy demonstrates strong cash flow.
• Refinancing: Replacing existing debt with new financing. Banks evaluate the pharmacy’s current performance and whether refinancing improves debt service capacity.
• Equipment and technology: Financing for automation, dispensing systems, or software upgrades. Often structured as separate equipment loans with shorter terms.

How Banks Analyze Pharmacy Financial Statements

Financial statement analysis forms the core of every bank’s underwriting process.

Revenue and Prescription Volume Verification

Banks do not simply accept the seller’s representations. They verify:

Monthly revenue trends: Banks request 24 to 36 months of monthly revenue data to identify seasonality, trends, and anomalies. A pharmacy showing consistent month-over-month revenue growth is far more attractive than one with erratic patterns.

Prescription count documentation: Monthly prescription reports from pharmacy software systems showing new scripts, refills, total script count, and average script value. Banks compare these counts against revenue to verify consistency.

Third-party payer reconciliation: Monthly remittance summaries from provincial drug plans and private insurers. Banks verify that reported revenue matches actual payments received from these sources.

Front-shop vs. prescription revenue: Banks analyze the split between prescription revenue (more stable, predictable) and front-shop retail sales (more variable, discretionary). Pharmacies with roughly 75% to 85% of revenue from prescriptions are viewed favourably.

Gross Margin Analysis

Banks examine gross profit margins closely because pharmacy margins vary based on payer mix, purchasing power, and operational efficiency.

• Typical community pharmacy gross margins: roughly 25% to 35% depending on generic vs. brand mix, payer types, and front-shop performance. Banks know industry benchmarks and flag pharmacies outside normal ranges.
• Margin stability over time: Consistent gross margins (moving only a couple of percentage points year over year) signal stable operations. Declining margins indicate pricing pressure, increased competition, or operational issues.
• Cost of goods sold verification: Banks may request sample wholesaler invoices to verify inventory costs and ensure markup calculations are reasonable.

Operating Expense Scrutiny

Banks analyze operating expenses as a percentage of revenue and compare them to industry norms. The ranges below are typical ranges we see in community pharmacies, shown for illustration; they are not published lender benchmarks.

Red flags in expense analysis:

• Rent exceeding 10% of revenue (unsustainable lease burden)
• Payroll over 20% of revenue (overstaffing or high wage pressure)
• Significant one-time expenses not properly explained
• Related-party transactions (owner renting building to pharmacy at inflated rates)

EBITDA Normalization and Bank Adjustments

This is where seller preparation critically affects buyer financing.

Banks perform their own EBITDA normalization, often more conservatively than brokers or sellers. They scrutinize every add-back and adjustment claimed in the normalized EBITDA calculation.

Add-backs banks typically accept (each lender decides case by case):

• Owner’s salary above market replacement cost (with supporting salary survey data)
• Well-documented personal expenses (vehicle, travel, phone) with receipts and logs
• Clearly one-time expenses that ran through the income statement (one time legal fees, an expensed emergency repair, uninsured costs from a specific casualty event). Capitalized renovations and equipment never reduced EBITDA, so they are not add backs; lenders look at capital spending separately as a cash need
• Rent adjustments to market rates (with commercial lease comparables)

Add-backs banks often reject or heavily discount:

• Manufacturer rebates or professional allowances unless guaranteed by long-term contracts
• Projected cost savings (“I could reduce staff by one person”)
• Family member wages without proof that the role is unnecessary or overpaid
• Personal expenses exceeding reasonable business justification
• Any adjustment lacking clear documentation

Example of bank conservatism:

A seller’s normalized EBITDA presentation shows $375,000, built on four add-backs:

• $50,000 owner excess compensation (documented with salary surveys): banks accept
• $18,000 one-time legal fees (invoices provided): banks accept
• $35,000 in family member wages with no documentation that the role is redundant: banks reject
• $22,000 “projected delivery cost reduction” (not historical): banks exclude entirely

Bank-adjusted EBITDA: $375,000 - $35,000 - $22,000 = $318,000

This $57,000 difference directly impacts the loan amount the bank will approve because it flows through to cash available for debt service and the Debt Service Coverage Ratio.

Debt Service Coverage Ratio: The Most Critical Metric

DSCR is the single most important number in pharmacy acquisition financing. It determines whether your loan gets approved and at what amount.

What DSCR Means

Debt Service Coverage Ratio measures whether a business generates enough cash flow to cover its debt obligations with a safety margin.

DSCR formula:

DSCR = Cash available for debt service / Annual debt service

Where:

• Bank-adjusted EBITDA = the lender’s version of normalized EBITDA. Like normalized EBITDA, it already deducts a market salary for every role, including the pharmacist manager role the buyer will fill. That salary is not deducted again.
• Cash available for debt service = bank-adjusted EBITDA minus income taxes, minus maintenance capital spending (fixtures, computers, minor equipment), and sometimes minus owner draws above the market salary already deducted. It is not the same as EBITDA.
• Annual debt service = all scheduled principal and interest payments on all debt (the term loan plus any vendor take-back, equipment loans or other borrowing)

Lenders define these terms differently, so ask yours for its exact formula. If a lender starts from earnings before any owner salary (as SDE does), it will deduct a market salary for the owner once.

Example calculation (illustrative):

A pharmacy has bank-adjusted EBITDA of $300,000. That figure already deducts a $120,000 market salary for the pharmacist manager role, which the buyer will fill.

The buyer wants a $1,200,000 loan at a 6.5% fixed rate with a 10 year amortization and monthly payments. The monthly payment is $13,625.76, so annual debt service is $163,509.

DSCR = $260,000 / $163,509 = 1.59x

Minimum DSCR Requirements

In our experience, many lenders look for a DSCR of roughly 1.20x to 1.30x on pharmacy acquisition loans, with 1.25x a common benchmark. BDC’s guidance on borrowing capacity also cites 1.25x as a common benchmark for its fixed charge coverage ratio, a similar measure. These are typical observations, not fixed rules: each lender sets its own threshold and its own definition of cash flow.

A DSCR of 1.25x means the pharmacy generates $1.25 of cash available for debt service for every $1.00 of debt payment. This 25% cushion protects the lender if revenue declines, expenses increase, or unexpected issues arise. Below the lender’s threshold, expect the lender to ask for a different structure, such as a higher equity contribution.

How lenders tend to view DSCR (our observations; outcomes vary by lender and deal):

How DSCR Determines Maximum Loan Amount

Banks work backward from required DSCR to calculate the maximum loan they will approve.

Formula:

Maximum annual debt service = Cash available for debt service / Required DSCR

Example (illustrative, same pharmacy as above):

Cash available for debt service is $260,000 ($300,000 bank-adjusted EBITDA, less $25,000 of estimated taxes and $15,000 of maintenance capital spending). Assume the lender uses 1.25x.

Maximum annual debt service = $260,000 / 1.25 = $208,000

At a 6.5% fixed rate, 10 year amortization and monthly payments, annual payments of $208,000 support a loan of about $1,526,500.

DSCR is not the only limit. Lenders also cap the loan as a share of the purchase price. Suppose the price is $1,750,000: $1,500,000 for the operating business (5x the $300,000 of normalized EBITDA, covering equipment, leaseholds and goodwill) plus $250,000 of inventory at cost. If this lender caps the loan at 80% of the price:

• Maximum by DSCR: about $1,526,500
• Maximum by loan to value (80% of $1,750,000): $1,400,000
• Bank loan: $1,400,000 (the lower of the two)
• Buyer equity: $350,000 (20% down payment)

On a $1,400,000 loan, annual debt service is $190,761 ($15,896.72 per month), so the DSCR is $260,000 / $190,761 = 1.36x.

This is why accurate EBITDA normalization matters so much. When DSCR is the binding limit, every additional $10,000 of cash available for debt service supports roughly $58,700 of additional borrowing (at a 1.25x DSCR, 6.5% interest, and 10 year amortization).

Prescription Counts, Payer Mix, and Margin Stability

Beyond financial statements, banks evaluate operational metrics that indicate business health and risk.

Prescription Volume and Trends

Stable or growing prescription counts demonstrate market strength and customer loyalty.

What banks examine:

• Total monthly script counts for 24 to 36 months
• New vs. refill ratio: higher refill percentages (often 65% to 75% of total) indicate a loyal patient base with chronic medication needs
• Seasonal patterns: some variation is normal, but extreme swings suggest instability
• Recent trends: banks are particularly concerned about declining script counts in the most recent 6 to 12 months

Red flags:

• Script counts declining 10% or more year over year without clear explanation
• Large single-month drops (may indicate loss of a major clinic relationship or institutional contract)
• Heavy dependence on a single prescriber (if one doctor retires or moves, script volume collapses)

Example of script volume impact:

Pharmacy A: 200 scripts per day on average, stable for 3 years. Pharmacy B: 200 scripts per day on average, but declined from 240 scripts per day two years ago.

Banks view Pharmacy A as far less risky despite identical current volume because Pharmacy B’s trend suggests competitive pressure or market share loss.

Payer Mix Analysis

Payer mix affects both revenue stability and margin predictability.

An illustrative payer mix lenders tend to be comfortable with (our observation, not a lender rule):

Risk factors (examples):

• Over 60% of revenue from provincial plans may signal margin pressure
• Over 30% from a single nursing home or institution creates concentration risk
• A high cash pay percentage (40% or more) may indicate lack of insurance access in the community or a transient population

Banks prefer diversified payer mixes because they reduce the impact of any single payer changing reimbursement terms or a contract ending.

Margin Stability and Sustainability

Consistent gross and net margins over time demonstrate operational stability.

What banks want to see:

• Gross margins that move only a couple of percentage points year over year
• Net margins (EBITDA as a percentage of revenue) stable or improving
• An explanation for any significant margin changes

Concerns that arise:

• Declining gross margins (suggests pricing pressure or a shift to lower-margin products)
• Improving margins solely due to one-time rebates or temporary situations
• Margins significantly above or below industry benchmarks without clear justification

Treatment of Rebates and Professional Allowances

Rules on manufacturer rebates and professional allowances differ by province and change over time. Ontario, for example, prohibits rebates to pharmacies subject to defined exclusions for ordinary commercial terms; other provinces regulate them in different ways. Check the current rules in your province with your advisor. Separately from what is legal, lenders treat this income cautiously when they judge whether it will continue.

Bank Perspective on Rebate Income

Rebates are viewed as less reliable than core dispensing revenue because:

• They depend on manufacturer discretion and can change or end
• Provincial governments may regulate or eliminate them (as Ontario did)
• They are not contractually guaranteed long term
• They can fluctuate based on generic pricing and formulary changes

How banks handle rebate income (examples of approaches we have seen, not fixed rules):

• Conservative approach (often seen): The lender excludes or heavily discounts rebate income unless the seller provides evidence of multi-year contracts supporting continuation.
• Moderate approach: The lender includes part of the rebates in EBITDA but requires a higher DSCR (for example 1.30x instead of 1.25x) to provide additional cushion.
• Lenient approach (less common): Some lenders include the full rebate income if it has been stable for several years and is a small share of total EBITDA.

Example:

A pharmacy shows $400,000 normalized EBITDA, including $80,000 in manufacturer rebates (20% of EBITDA).

Conservative bank approach: bank-adjusted EBITDA of $320,000 (excludes all rebates), with the loan amount based on $320,000.

Moderate bank approach: bank-adjusted EBITDA of $360,000 (includes 50% of rebates as sustainable), but the bank requires a 1.30x DSCR instead of 1.25x.

To keep it simple, assume the same $40,000 is deducted for income taxes and maintenance capital spending in both cases. Cash available for debt service is then $280,000 (conservative) or $320,000 (moderate). At 6.5% over a 10 year amortization, $280,000 / 1.25 = $224,000 of annual debt service supports about $1,644,000, while $320,000 / 1.30 = $246,154 supports about $1,806,500. The difference in these approaches can mean $100,000 or more (here about $162,600) in loan approval amount.

Lease Terms, Location, and Landlord Considerations

The pharmacy’s lease and location significantly affect financing approval because they impact business continuity and risk.

Lease Term Requirements

In our experience every lender ties the amortization to the remaining lease term including solid renewal options, so a 10 year amortization usually means about 10 years of lease security, and up to 12 years is available on a 12 year lease in the current market. This is how lenders behave in the deals we work on, not a published bank rule, so treat the lease as a key due diligence item and confirm your lender’s requirement early. Our article will the bank accept your pharmacy lease? covers which options a lender counts and what a short lease does to the numbers.

Why this matters: Banks do not want to finance a pharmacy that might lose its location mid-loan. Without a secure location, the business value collapses and the collateral becomes worthless.

If the lease term is short, banks may:

• Reduce the loan term to match the lease (for example, a 7 year loan for 7 years remaining on the lease)
• Require a higher down payment to reduce exposure
• Request landlord letters confirming renewal options or willingness to renew
• In extreme cases, reject the loan entirely

Red flags:

• Less than 3 years remaining on the lease with no renewal options
• Lease renewal options at “market rate to be determined” (too much uncertainty)
• Landlord unwilling to confirm future renewal
• Pending sale of the property or landlord financial distress

Lease Assignment and Landlord Consent

For asset sales, the lease must be assignable to the buyer.

What lenders usually want to see:

• Landlord consent letter confirming willingness to assign the lease
• No significant rent increases upon assignment
• Assignment provisions clearly stated in the lease agreement
• Landlord financial stability (banks worry if the landlord is in financial trouble)

Timeline consideration: Landlord approval for lease assignment often takes 2 to 4 weeks, sometimes longer. Banks will not fund until this approval is secured, so start this process immediately after LOI acceptance.

Location Quality Assessment

Banks assess location quality because it affects the pharmacy’s competitive position and long-term viability.

Positive location factors:

• Proximity to medical clinics or hospitals (within 1 to 2 km)
• High-traffic retail areas with good visibility and parking
• Growing or stable residential communities
• Limited direct pharmacy competition within 2 to 3 km
• Good demographics (aging population, higher income, insurance coverage)

Negative location factors:

• Isolated locations with declining foot traffic
• Pending closure of nearby anchor tenants or medical facilities
• New chain pharmacy opening nearby
• Demographic shifts (neighbourhood transitioning to a younger, healthier population)
• Difficult access, poor parking, or safety concerns

Strong locations support higher loan amounts because they reduce business risk. Marginal locations may result in a smaller loan or higher equity requirements.

Personal Guarantees and Borrower Financial Strength

Personal guarantees are common in Canadian pharmacy acquisition financing.

What Personal Guarantees Mean

A personal guarantee makes the borrower personally liable for the business debt, up to the terms of the guarantee. If the pharmacy fails and cannot repay the loan, the bank may be able to pursue the borrower’s personal assets (home, investments, savings).

Terms to read and negotiate (the signed guarantee governs):

• Amount: a guarantee can be unlimited (covering the whole debt) or limited to a set amount
• Joint and several liability: with multiple guarantors, each may be responsible for the entire debt
• Continuity and release: many guarantees continue until the debt is repaid, even if the business is restructured; whether and when you can be released depends on the wording

Have your own lawyer review the guarantee before you sign.

Why banks require them: Pharmacy goodwill value is intangible. If the business fails, the bank recovers little from selling used equipment and inventory. Personal guarantees ensure the borrower has a strong incentive to make the business succeed.

Borrower’s Personal Financial Position

Banks evaluate the borrower’s personal balance sheet alongside the business financials.

What banks examine:

• Personal credit score: Roughly 680 or higher for most pharmacy loans, with 720+ helping on terms (each lender sets its own criteria)
• Net worth: Total assets minus liabilities. Lenders often like to see net worth at least equal to the down payment plus 6 to 12 months of living expenses
• Existing debt obligations: Mortgage payments, car loans, credit card balances, and student loans all affect debt service capacity
• Income stability: If the buyer currently earns income from employment, banks may include a portion of it in cash flow calculations during the transition period
• Liquid assets: Cash, investments, and readily accessible funds demonstrate financial cushion

Example:

Buyer A: excellent credit (780), $300,000 net worth, minimal debt. Buyer B: fair credit (680), $100,000 net worth, $200,000 in existing mortgage and student loans.

For the same pharmacy acquisition, Buyer A receives better interest rates, higher loan-to-value, and faster approval. Buyer B may face higher equity requirements or loan rejection. Strong personal finances can overcome marginal business cash flow. Weak personal finances can cause rejection even with strong business performance.

Typical Loan Structures and Down Payment Requirements

Understanding standard pharmacy loan structures helps both buyers and sellers set realistic expectations before a pharmacy for sale ever reaches the offer stage.

Down Payment and Loan-to-Value Ratios

Typical down payment ranges we see (they vary by lender and deal):

Loan-to-Value (LTV) ratios: In the current market we see lenders finance from 80% up to 100% of the purchase price for qualified buyers with a good lease, subject to credit approval. A short lease pushes the down payment up faster than almost anything else.

What the purchase price includes: Down payment percentages apply to the total transaction value: the price of the operating business (equipment, fixtures, leaseholds and goodwill, which the EBITDA multiple values together), plus inventory at cost, plus any real estate if it is part of the deal.

Example structure:

• Purchase price: $1,500,000 ($1,200,000 for the operating business, including equipment, leaseholds and goodwill, plus $300,000 inventory at cost)
• Bank financing (illustrative 75% LTV): $1,125,000
• Buyer equity required: $375,000 (25%)

Interest Rates and Loan Terms

Interest rates vary based on Bank of Canada rates, borrower creditworthiness, and loan structure.

Illustrative ranges we have seen (get current quotes; pricing changes with rates and lender appetite):

• Prime-based variable rates: Prime plus 0.5% to 2.0%, often around Prime plus 1.0% for qualified borrowers
• Fixed rates: In 2026, generally 6.0% to 8.5% depending on term length and borrower profile

Loan amortization periods:

• 10 years is most common for pharmacy acquisition loans
• 7 years for smaller loans or higher-risk situations
• 15 years occasionally available for very strong pharmacies with experienced buyers
• 5 years typical for equipment financing or working capital lines

Term vs. amortization: Many loans have 5 year terms with 10 year amortization, meaning the payment is based on a 10 year repayment schedule, but the loan comes due after 5 years with a balance still owing. At that point it must be renewed or refinanced, and the rate, payment and conditions are set by the lender at renewal. Renewal is not automatic, so a weaker pharmacy or a higher rate environment at renewal is a real risk to plan for.

Additional Financing Components

• Working capital line of credit: Banks often provide a revolving line of credit (commonly $50,000 to $150,000) to manage cash flow fluctuations, pay suppliers, and cover inventory purchases.
• Equipment financing: Separate equipment loans may be available for automation, dispensing systems, or technology upgrades, often with 3 to 5 year terms.
• Inventory financing: Some banks structure inventory as a separate loan or line of credit since it turns over regularly and has liquidation value.

Differences Between Major Banks and Credit Unions

While lending criteria are similar across institutions, nuances exist between major banks and credit unions.

Major Banks (RBC, Scotiabank, TD, BMO, CIBC, National Bank)

Advantages:

• Specialized healthcare teams: Dedicated advisors who understand pharmacy economics and can streamline approvals
• Established programs: Pre-built pharmacy acquisition loan products with standard terms
• National reach: Can finance pharmacies anywhere in Canada
• Higher lending limits: Capacity to finance multi-million dollar transactions or multiple locations
• Competitive rates: Large banks often offer the best interest rates for well-qualified borrowers
• Comprehensive services: Full suite of banking, wealth management, and insurance products

Potential drawbacks:

• More standardized approval criteria (less flexibility for unique situations)
• Can be slower to adjust terms for marginal deals
• May require stronger financial metrics (higher DSCR, larger down payments)

Bank pharmacy lending programs:

• Scotiabank: Banking for Pharmacists, including the Scotia Professional Plan with up to 100% financing for qualified buyers, subject to credit approval
• RBC Healthcare, with practice acquisition financing and dedicated healthcare specialists
• TD Banking for Healthcare Professionals, offering tailored lending for practice purchases
• Canada Small Business Financing Program, a government-backed option that can support equipment and leasehold components of smaller deals

Credit Unions (Meridian, Coast Capital, Servus, Conexus, local credit unions)

Advantages:

• Relationship-based lending: More willing to consider the full borrower story beyond just numbers
• Local decision-making: Branch or regional managers often have lending authority
• Flexibility: Can structure creative solutions for marginal deals
• Community focus: May prioritize keeping local pharmacies in operation
• Potentially faster approvals: Fewer bureaucratic layers for smaller loans

Potential considerations:

• Higher interest rates: Sometimes somewhat higher than major banks
• Lower lending limits: May have lower lending limits than major banks, depending on credit union size
• Regional limitations: Credit unions typically only lend in their operating provinces
• Fewer specialized healthcare advisors: May have less pharmacy-specific expertise

When to Choose Each

Choose major banks if: You have a strong credit and financial profile, the pharmacy has excellent cash flow with comfortable debt coverage, you want the lowest possible interest rate, you need a large loan (over $2 million), or you prefer working with specialists who understand pharmacy transactions.

Choose credit unions if: Your financial profile is slightly below major bank thresholds, you value personal relationships and local decision-making, the pharmacy is in a smaller community where the credit union operates, you need more flexible terms or creative structuring, or you have existing relationships with the credit union.

Consider both: Many buyers approach 2 to 3 lenders simultaneously to compare terms and rates. This is acceptable and common practice.

Provincial Considerations for Pharmacy Financing

Provincial differences in pharmacy economics affect how banks evaluate financing applications.

British Columbia:

• BC PharmaCare’s maximum dispensing fee of $11.00 per eligible PharmaCare claim limits public plan revenue (it is a PharmaCare limit, not a cap on every fee)
• PharmaCare income-based deductible creates cash-pay seasonality
• Rural incentive programs add modest revenue support for qualifying pharmacies
• Lenders weigh how this fee environment affects margins; we have not seen a fixed BC specific DSCR rule

Alberta:

• Public plan dispensing fees rose on 1 October 2026 to $12.35 for prescriptions under 84 days’ supply and $13.50 for 84 days or more
• Professional service billing opportunities increase revenue potential, within a $13,000 per pharmacist rolling 28 day cap on services in force since 26 June 2026
• A lender still assesses the whole pharmacy, not one fee line, and applies its own coverage requirement

Ontario:

• Large market with high pharmacy density and competition
• The prohibition on manufacturer rebates (subject to defined exclusions) has compressed margins
• ODB provides high volume but lower margin revenue
• Banks scrutinize competitive positioning and market share carefully
• Rural dispensing fee uplift helps support pharmacies in smaller communities

Quebec:

• Regulated professional allowance caps affect profitability
• Widely reported pharmacist staffing pressure can drive up labour costs
• Lenders may factor staffing risk into the structure they offer
• Language requirements and the regulatory environment add complexity

Other provinces:

• Smaller markets with less pharmacy density
• Rural pharmacies often serve as essential community infrastructure
• Some lenders may show more flexibility if the pharmacy is the only one serving the community
• Credit unions are often more active than major banks in smaller provinces

Practical Steps for Buyers to Secure Financing

1. 6 to 12 months before purchase: Review your personal credit report and address any issues. Pay down high-interest debt.
2. 3 to 6 months before: Accumulate down payment funds. Verify liquidity and source of funds.
3. 3 to 4 months before: Meet with 2 to 3 lenders (banks and credit unions) to discuss pharmacy financing programs and get pre-qualification.
4. Provide lenders with personal financial statements, credit authorization, and a preliminary business plan.
5. Upon identifying a target pharmacy: Share the pharmacy’s financial information with your lender for preliminary approval. Browsing current pharmacy listings with pre-qualification in hand puts you in a far stronger negotiating position.
6. Obtain a conditional loan approval letter before submitting a Letter of Intent to the seller.
7. After LOI acceptance: Submit a complete loan application with three years of pharmacy financial statements, a business plan and cash flow projections, lease documentation, the personal guarantee, and proof of down payment.
8. Work with your lender through the underwriting process, providing additional documentation as requested.
9. Obtain the final loan commitment letter (typically 30 to 45 days after full application submission).
10. Coordinate closing with your lawyer, the seller’s lawyer, and the lender to ensure funds are available on closing day.

Practical Guidance for Sellers

Sellers can significantly improve deal success rates by understanding buyer financing challenges.

Prepare financial documentation. Provide organized, complete financial records: three years of accountant-prepared financial statements, a normalized EBITDA schedule with clear explanations, monthly prescription count reports, a payer mix analysis, and lease documentation. Clean, organized financials speed buyer approvals.

Price realistically and test financeability. Value comes from normalized EBITDA and the market; our pharmacy valuation guide explains how realistic multiples are built. Financing is a separate test of whether a typical buyer can actually close at that price, so check that the asking price still works on bank-adjusted (not just broker-normalized) EBITDA. Overpricing based on aggressive add-backs leads to buyer financing failures and collapsed deals.

Address lease issues early. If your lease has less than 5 years remaining, negotiate a renewal or extension before listing. Buyers cannot secure adequate financing without lease certainty.

Be flexible on structure. Consider vendor take-back financing (a seller-provided loan for a portion of the purchase price) if it helps bridge buyer financing gaps. In our experience, a 10% to 20% vendor take-back for 2 to 3 years can make marginal deals work, if the buyer’s lender agrees to it (lenders often set conditions on when vendor payments can be made).

Qualify buyers before exclusivity. Require proof of financing pre-approval or proof of funds before granting exclusivity periods. Do not waste months on buyers who cannot actually secure financing for your pharmacy for sale.

Conclusion: Financing Determines Deal Success

Understanding Canadian bank financing criteria is not optional for successful pharmacy transactions. Sellers who ignore how banks evaluate their businesses price incorrectly and attract unqualified buyers. Buyers who do not prepare financially waste time pursuing pharmacies they cannot afford.

The good news is that pharmacy financing in Canada follows recognizable patterns. Each lender sets its own criteria, but the questions they ask are consistent, and DSCR gives everyone a common yardstick. Preparing properly improves your chances of approval.

Start early. Organize your financials. Understand what banks will actually accept in EBITDA calculations. Know your DSCR. Secure your lease. And work with lenders who understand pharmacy transactions.

The difference between a deal that closes smoothly and one that collapses often comes down to financing preparation that started months before the first offer. If you are buying or selling a pharmacy and need guidance on positioning the business for successful financing, contact us for a confidential consultation.